Axonics, Inc.

Good day and thank you for standing by. Welcome to the Anonix Q2 2022 results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that session, you'll need to press star 1 1 on your phone. Please be advised that today's conference is being recorded. And I will now like to hand the conference over to your host today, Mr. Neal Beloker. Mr. Beloker, please go ahead.

Thank you. Good afternoon, and thank you for joining Axonics' second quarter 2022 results and update call. Presenting on today's call are Raymond Cohen, Chief Executive Officer, and Dan Duren, President and Chief Financial Officer. Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events, prospects, or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to a number of risks, uncertainties, assumptions, and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in Axonix's filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Listeners are cautioned not to place undue reliance on these four statements, which speak only as of today's date, August 1st, 2022. Except as required by law, Exonix undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances, or unanticipated events that may arise. I would now like to turn the call over to Ray.

Excellent. Thanks, Neil. I would like to welcome everyone joining this afternoon's call. We're very proud of our second quarter 2022 financial results. Exonix generated total revenue of $69 million in the second quarter of 2022, which represents growth of 50% year-over-year. This record revenue result reflects growing demand for our best-in-class incontinence solutions. More specifically, cyclonal modulation revenue was $55.8 million, an increase of 39% year-over-year. This record level of FNM revenue is primarily attributable to the broad U.S. commercial launch of our recharge-free system, dubbed the Exonix F15, which, by the way, has exceeded our own high expectations. Now that the pandemic is receding, we are seeing signs that procedural volume for cyclinomodulation is expanding. In addition, we are continuing to gain share from the incumbent as we continue to make progress on our path to sequential modulation market leadership. Turning to Bulk Med, revenue in the second quarter was $13.2 million, including $10.2 million that was generated in the United States. Results were driven by solid reorder rates from existing accounts and the onboarding of new accounts. We now expect approximately 50,000 women will have their stress urinary incontinence symptoms treated with BocaMed during calendar year 2022. And we're just scratching the surface of what is possible in the large and highly underserved and under-penetrated female stress urinary incontinence market. Based on this quarter's strong results and positive business momentum, we are raising our fiscal year 2022 total company revenue guidance to $253 million from prior revenue guidance of $238 million, which represents growth of 40% compared to 2021. I'll provide some additional color and business updates prior to the Q&A session. So for now, I'm going to turn the call over to Dan for his detailed review of second quarter financial results. Dan?